86236-37-5

Upstream product

• 272-14-0 thieno[3,2-c]pyridine 
• 109-72-8 n-butyllithium 
• 124-38-9 carbon dioxide 
• 10177-29-4 4-chloronicotinic acid 
• 189449-41-0 4-chloro-3-(hydroxymethyl)pyridine 
• 114077-82-6 4-chloronicotinaldehyde 
• 478149-07-4 methyl thieno[3,2-c]pyridine-2-carboxylate 

Downstream Products

• 1018953-37-1 1-(thieno[3,2-c]pyridin-2-yl)ethan-1-one 

Relevant academic research and scientific papers

NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF

The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-β, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I: 1where in W is 2These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which α7 is known to be involved.

Thieno and furopyridinium-substituted cephalosporins

Cephalosporin compounds substituted in the 7-position by a 2-(5- or 6-membered heterocyclic)-2-oximinoacetylamino group and in the 3-position with a thienopyridinium methyl group or a furopyridinium methyl group are broad spectrum antibiotics highly effective in combating bacterial infections of gram-negative and gram-positive microorganisms. The cephalosporins are best prepared by reacting a silylated 7-[2-(heterocyclic)-2-oximinoacetylamino-3-iodomethyl-3-cephem-4-carboxylic acid with the thienopyridine or the furopyridine. Pharmaceutical formulations comprising a compound of the invention and a method for treating bacterial infections comprising their use are also provided.